

DAFTAR PUSTAKA

1. Versteeg HV, Heemskerk JW, Levi M, Reitsma PH. New fundamentals in hemostasis. *Physiol Rev.* 2013;93:327–358.
2. Sukrisman, Lugyanti. Trombosis vena dalam dan emboli paru. Buku ajar ilmu penyakit dalam Fakultas Kedokteran UI. Jakarta: FKUI. 2006:802-804.
3. Naess SC, Christiansen P, Romundstad. Incidence and mortality of venous thrombosis: a Population based study. *Journal of thrombosis and haemostasis.* 2007;5:4:692–699.
4. US Department of Health and Human Services. The Surgeon General's call to action to prevent deep vein thrombosis and pulmonary embolism. Washington, DC: US Department of Health and Human Services. 2008.
5. National Institute of Clinical Studies. The Incidence and Risk Factors for Venous Thromboembolism in Hospitals in Western Australia 1999-2001: Prepared by the School of Population Health, University of Western Australia. 2005.
6. Simona CF, Denisa MA, Ana MM, Ioan CS, Dinu A. Venous thromboembolism following major orthopedic surgery. *Journal of Clinical Medicine* 2013; 8(2): 189-194
7. Hartono F, Ismail HD. Insidensi trombosis vena dalam pasca operasi orthopedi risiko tinggi tanpa tromboprolifaksis. *J Indon Med Assocl.* 2011;61;6.

8. Falck-Ytter Y, Francis CW, Johanson NA, Curley C, Dahl OE, Schulman S. Prevention of VTE in orthopedic surgery patients: Antithrombotic therapy and prevention of thrombosis, 9th ed: American college of chest physicians evidence-based clinical practice guidelines. *Chest*. 2012;141;278-325.
9. Piovella F, Wang CJ, Lu H, Lee K, Lee LH, Lee WC, et al. Deep-vein thrombosis rates after major orthopedic surgery in Asia: an epidemiological study based on postoperative screening with centrally adjudicated bilateral venography. *J Thromb Haemost*. 2005; 3: 2664-70
10. Leizorovicz A, Turpie AGG, Cohen AT, Wong L, Yoo MC, Dans A . The SMART study group. Epidemiology of venous thromboembolism in Asian patients undergoing major orthopedic surgery without thromboprophylaxis. The SMART study. *J Thromb Haemost*. 2005;3:28–34.
11. Fuji T, Fujita S, Ochi T. Fondaparinux prevents venous thromboembolism after joint replacement surgery in Japanese patients. *Int Orthop*. 2008;32 4:443-51.
12. Previtali E, Bucciarelli P, Passamonti SM, Martinelli I. Risk factors for venous and arterial thrombosis. *Blood Transfus*. 2011;9:120-38.
13. Watanabe H1, Sekiya H, Kariya Y, Hoshino Y, Sugimoto H, Hayasaka S. The incidence of venous thromboembolism before and after total knee arthroplasty using 16-row multidetector computed tomography. *J Arthroplasty*. 2011;26;8:1488-93.

14. AAOS. Total knee replacement. River road. American academy of orthopaedic surgeons. 2009.
15. Eugênio L, Leme G, Turolla G. Prophylaxis of venous thromboembolism in orthopaedic surgery. *Rev Bras Ortop.* 2012;47;6:685-93.
16. Rajpura,A and Board T. Complications following total hip arthroplasty. *J Arthroplasty* . 2013;1-40.
17. Eriksson BI, Eriksson E, Risberg B. Impaired fibrinolysis and postoperative thromboembolism in orthopedic patients. *Thromb Res.* 1991;62:55-64.
18. William D. Fisher, MD. Impact of venous thromboembolism on clinical management and therapy after hip and knee rthroplasty. 2011. *J can chir:* 54;5;344-351.
19. Bittar D, Javad P. Biological response to prosthetic debris. *World J Orthop.* 2015 March 18;6:172-189.
20. Reikeras O, Borgen P. Activation of markers of inflammation, coagulation and fibrinolysis in musculoskeletal trauma. 2014; 9;11.
21. Bern MM, Hazel D, Reilly DT. Effects of anticoagulation on markers of activation of clotting following major orthopedic surgery. *International Journal of Laboratory Hematology.* 2015;37:673-679.
22. Yukizawa Y, Inaba Y, Watanabe SI, Yajima S, Kobayashi N, Ishida T. Association between venous thromboembolism and plasma levels of both soluble fibrin and plasminogen-activator inhibitor 1 in 170 patients undergoing total hip arthroplasty. *Acta Orthopaedica.* 2012;83;1:14-21.

23. Inaba Y, Yukizawa Y, Saito T. Coagulation and fibrinolysis markers and their use for the prediction of high risk patients with venous thromboembolism following total hip arthroplasty. *J Fibrinolysis and Thrombolysis*. 2014;164-176.
24. Borgen PO, Dahl OE, Reikeras O. Biomarker of coagulation and fibrinolysis during cemented total hip arthroplasty with pre-versus postoperative start of thromboprophylaxis. 2013;1-7.
25. Green L, Lawrie AS, Shelain P, Hossain F, Chitolie A, Mackie IJ. The impact of elective knee/hip replacement surgery and thromboprophylaxis with rivaroxaban or dalteparin on thrombin generation. *British Journal of Haematology*. 2010;151;469–476.
26. Geerts WH, Bergqvist D, Pineo GF. Prevention of venous thromboembolism: American college of chest physicians evidence-based clinical practice guidelines (8th edition). *Chest*. 2008;133:381–453.
27. Warwick D, Friedman RJ, Agnelli G, Gil-Garay E, Johnson K, FitzGerald G, et al. Insufficient duration of venous thromboembolism prophylaxis after total hip or knee replacement when compared with the time course of thromboembolic events: findings from the Global Orthopaedic Registry. *J Bone Joint Surg Br*. 2007;89;6:799-807.
28. Pottier P, Hardouin JB, Lejeune S. Immobilization and the risk of venous thromboembolism. A meta-analysis on epidemiological studies. *Thrombosis Research*. 2009;124:468–76.
29. Goodnight SH, Hathaway WE. Mechanisms of hemostasis and thrombosis. *J Tromb Haemost*. 2001;3-16.

30. Mackman N. New insights into the mechanism of venous thrombosis. *J clin invest.* 2012;122:2331-6.
31. Esmon CT. Basic mechanism and pathogenesis of venous thrombosis. *Blood.* 2009;23:225-9.
32. Murray RK., Bender DA., Botham K.M., Kennelly PJ, Rodwell VW. AChapter 51. Hemostasis & Thrombosis. In Harper's Illustrated Biochemistry. The McGraw-Hill Companies. 2012.
33. Kumar V, Abbas AK, Fausto N, Mitchell, RN. Robbins basic pathology 2007;86-93.
34. Wilson, MG, Kelley, K, Thornhill, TS. Infection as a complication of total knee-replacement arthroplasty. Risk factors and treatment in sixty-seven cases. *J Bone Joint Surg Am.* 2005;72:87-81.
35. Sørensen JV. Haemostatic activation after surgery and trauma relationship to clinicopathological findings. Aarhus Universitet.1996;1-36
36. White, RJ. Thrombin and platelets in pulmonary hypertension: A Lot more than clot. *Advances in pulmonary hypertension.* 2012;1;11:19-24.
37. Kroegel C, Reissig A. Principle mechanisms underlying venous thromboembolism: epidemiology, risk factors, pathophysiology and pathogenesis. *Respiration.* 2003;70:7-30.
38. Januel JM, Chen G, Ruffieux C, Quan H, Douketis JD, Crowther MA, et al.Symptomatic in-hospital deep vein thrombosis and pulmonary embolism following hip and knee arthroplasty among patients receiving recommended prophylaxis: a systematic review. *JAMA.* 2012;307:294-303.

39. Purdue PE, Koulouvaris P, Potter HG, Nestor BJ, Sculco TP. The cellular and molecular biology of periprosthetic osteolysis. *Clin Orthop Relat Res.* 2007;454:251-61.
40. Edwin P, Chatzoudis N, Sioros V, Go G, Nigel E. Sharrock B. Markers of thrombin generation during resurfacing and noncemented total hip arthroplasty. A Pilot study. *Clin Orthop Relat Res.* 2011;469:535–540.
41. Friedman RJ, Gallus A, Gil-Garay E, FitzGerald G, Cushner F. Practice patterns in the use of venous thromboembolism prophylaxis after total joint arthroplasty—insights from the multinational global orthopedic registry (GLORY). *Am J Orthop.* 2010;39;9:14–21.
42. Fauci. Venous thrombosis. In: Harrison principles of internal medicine. 17th ed. USA: The McGraw-Hill Companies. 2008.
43. Bounameaux A, Perrier R. Diagnosis of venous thromboembolism: an update. *Vascular Medicine.* 2010;15:5:399–406.
44. Mohamed F, Abdelhamid, Robert S, Donald J, Adam K. Changes in thrombin generation, fibrinolysis, platelet and endothelial cell activity, and inflammation following endovascular abdominal aortic aneurysm repair. *J Vasc Surg.* 2012;55:41-6.
45. Carradi A, Lazzaro F, Cofranco E, Cortellaro M, Ravasif F, Bertocch F. Preoperative plasma level of prothombin fargment 1+2 correlative with risk of venous thorombosis after elective hip replacement. *Acta irthoaedica belgia.* 1999:65-1.

46. Pelzer H, Schwarz A, Stuber W. Determination of human prothrombin activation fragment 1 + 2 in plasma with an antibody against a synthetic peptide. *Thromb Haemost.*1991;65:153-159.
47. Ota S, Wada H, Abe Y, Yamada E, Sakaguchi A, Nishioka J. Elevated levels of prothrombin fragment 1 + 2 indicate high risk of thrombosis. *clin appl thromb hemost*; 2008;14;3:279-85
48. Cihan Ay, Vormittag R, Dunkler D, Simanek R, Chiriac AL, Drach J, et al. D-dimer and prothrombin fragment 1+2 predict venous thromboembolism in patients with cancer: Results from the vienna cancer and thrombosis Study. *J Clin Oncol.* 2011;27:4124-4129.
49. Bengt, Eriksson E, Gyzander E, Catrine A. Thrombosis after hip replacement relationship to the fibrinolytic system. *Acta Orthop Scand.* 1989;60(2):159-163.
50. Chapin JC, Hajjar KA. Fibrinolysis and the control of blood coagulation. *Blood Rev.* 2015;29;1:17-24.
51. Gordon D, Lowe, Frits, Simon G, Thompson, Rebecca M. Prediction of deep vein thrombosis after Elective hip replacement surgery by preoperative clinical and haemostatic variables: The ECAT DVT Study. *Thromb Haemost.* 1999;81:879–86
52. Lowe G, Rumley A, Woodward M, Morrison E, Pholipoe H, Lane A. Epidemiology of coagulation factors, inhibitors and activation markers: The Third Glasgow MONICA SurveyI. Illustrative reference ranges by age, sex and hormone use. *British Journal of Haematology.*1997;97;775–784.

53. Borris C, Breindahl M, Michael R. Prothrombin fragment 1+2 in relation to development of non-Symptomatic and symptomatic venous thromboembolic events following total knee replacement. *Thrombosis*. 2011;50-6.
54. Kageyawa K, Nakajima Y, Shibasaki M, Hashimoto S, Mizobe T. Increased platelet, leukocyte, and endothelial cell activity are associated with increased coagulability in patients after total knee arthroplasty. *Journal of Thrombosis and Haemostasis*. 2007;5:738–745.
55. Lopez JA, Paramo JR, Valenti F, Pardo S. Hemostatic markers in surgery: a different fibrinolytic activity may be of pathophysiological significance in orthopedic versus abdominal surgery. *Int J Clin Lab Res*. 1997;27;233-237.
56. Blanié A, Bellamy A, Rhayem Y, Flaujac C, Samama CM, Fontenay M, et al. Duration of postoperative fibrinolysis after total hip or knee replacement: A Laboratory follow-up study. *Thrombosis Research*. 2013; 6–11.
57. Trotti R, Siragusa S, Rondanelli M, Chezzi L, Citterio A, Melzi d'Eril GV, Piovella F. Fibrinolytic parameters in patients undergoing total hip replacement: relationship with the development of asymptomatic deep vein thrombosis and diagnostic usefulness of venous occlusion. *Haematologica January* 1997 82: 178-181.
58. Sudo A, Wada H, Nobori T, Yamada N, Ito M, Niimi R, et al. Cut-off values of Ddimer and soluble fibrin for prediction of deep vein thrombosis after orthopaedic surgery. *Int J Hematol*. 2009;89;5:572-6.

59. Mihara S, Sumi H, Yoneta T, Mizumoto H, Ikade R, Seki M, *et al.* A Novel fibrinolytic enzyme from earthworm *Lumbricus lubellus*. *Japanese J Physiol.* 1991;41:461-72.
60. Verma K, Pullycarla KK. Lumbrokinase A potent and stable fibrin-specific plasminogen activator. *International Journal of Bio-Science and Bio-Technology.* 2011;3:57-67.
61. Mukhayarjon. Pengaruh pemberian lumbrokinase terhadap fungsi hemostatis pada pasien diabetes melitus tipe 2 (tesis). Padang: Universitas Andalas, 2014.

